84 related articles for article (PubMed ID: 22628304)
1. A novel role for reciprocal CD30-CD30L signaling in the cross-talk between natural killer and dendritic cells.
Simhadri VL; Hansen HP; Simhadri VR; Reiners KS; Bessler M; Engert A; von Strandmann EP
Biol Chem; 2012 Jan; 393(1-2):101-6. PubMed ID: 22628304
[TBL] [Abstract][Full Text] [Related]
2. CD30 ligand/CD30 plays a critical role in Th17 differentiation in mice.
Sun X; Yamada H; Shibata K; Muta H; Tani K; Podack ER; Yoshikai Y
J Immunol; 2010 Aug; 185(4):2222-30. PubMed ID: 20639486
[TBL] [Abstract][Full Text] [Related]
3. Reverse signaling via CD30 ligand.
Wiley SR; Goodwin RG; Smith CA
J Immunol; 1996 Oct; 157(8):3635-9. PubMed ID: 8871664
[TBL] [Abstract][Full Text] [Related]
4. Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines.
Gruss HJ; DaSilva N; Hu ZB; Uphoff CC; Goodwin RG; Drexler HG
Leukemia; 1994 Dec; 8(12):2083-94. PubMed ID: 7528856
[TBL] [Abstract][Full Text] [Related]
5. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases.
Oflazoglu E; Grewal IS; Gerber H
Adv Exp Med Biol; 2009; 647():174-85. PubMed ID: 19760074
[TBL] [Abstract][Full Text] [Related]
6. The central role of CD30L/CD30 interactions in allergic rhinitis pathogenesis in mice.
Fuchiwaki T; Sun X; Fujimura K; Yamada H; Shibata K; Muta H; Podack ER; Kawauchi H; Yoshikai Y
Eur J Immunol; 2011 Oct; 41(10):2947-54. PubMed ID: 21739429
[TBL] [Abstract][Full Text] [Related]
7. Deciphering CD30 ligand biology and its role in humoral immunity.
Kennedy MK; Willis CR; Armitage RJ
Immunology; 2006 Jun; 118(2):143-52. PubMed ID: 16771849
[TBL] [Abstract][Full Text] [Related]
8. Increase in CD30 ligand/CD153 and TNF-alpha expressing mast cells in basal cell carcinoma.
Diaconu NC; Kaminska R; Naukkarinen A; Harvima RJ; Nilsson G; Harvima IT
Cancer Immunol Immunother; 2007 Sep; 56(9):1407-15. PubMed ID: 17268792
[TBL] [Abstract][Full Text] [Related]
9. Characterization of CD30/CD30L(+) Cells in Peripheral Blood and Synovial Fluid of Patients with Rheumatoid Arthritis.
Barbieri A; Dolcino M; Tinazzi E; Rigo A; Argentino G; Patuzzo G; Ottria A; Beri R; Puccetti A; Lunardi C
J Immunol Res; 2015; 2015():729654. PubMed ID: 26090498
[TBL] [Abstract][Full Text] [Related]
10. Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion.
Fischer M; Harvima IT; Carvalho RF; Möller C; Naukkarinen A; Enblad G; Nilsson G
J Clin Invest; 2006 Oct; 116(10):2748-56. PubMed ID: 16964309
[TBL] [Abstract][Full Text] [Related]
11. Interference of the CD30-CD30L pathway reduces atherosclerosis development.
Foks AC; Bot I; Frodermann V; de Jager SC; Ter Borg M; van Santbrink PJ; Yagita H; Kuiper J; van Puijvelde GH
Arterioscler Thromb Vasc Biol; 2012 Dec; 32(12):2862-8. PubMed ID: 23087358
[TBL] [Abstract][Full Text] [Related]
12. Proliferation of CD30+ T-helper 2 lymphoma cells can be inhibited by CD30 receptor cross-linking with recombinant CD30 ligand.
Willers J; Dummer R; Kempf W; Kündig T; Burg G; Kadin ME
Clin Cancer Res; 2003 Jul; 9(7):2744-54. PubMed ID: 12855655
[TBL] [Abstract][Full Text] [Related]
13. In rheumatoid arthritis soluble CD30 ligand is present at high levels and induces apoptosis of CD30(+)T cells.
Tinazzi E; Barbieri A; Rigo A; Patuzzo G; Beri R; Gerli R; Argentino G; Puccetti A; Lunardi C
Immunol Lett; 2014 Oct; 161(2):236-40. PubMed ID: 24447865
[TBL] [Abstract][Full Text] [Related]
14. Regulation of murine B cell growth and differentiation by CD30 ligand.
Shanebeck KD; Maliszewski CR; Kennedy MK; Picha KS; Smith CA; Goodwin RG; Grabstein KH
Eur J Immunol; 1995 Aug; 25(8):2147-53. PubMed ID: 7664777
[TBL] [Abstract][Full Text] [Related]
15. CD30 ligand is a target for a novel biological therapy against colitis associated with Th17 responses.
Sun X; Yamada H; Shibata K; Muta H; Tani K; Podack ER; Iwakura Y; Yoshikai Y
J Immunol; 2010 Dec; 185(12):7671-80. PubMed ID: 21068411
[TBL] [Abstract][Full Text] [Related]
16. Increased production of IFN-γ by natural killer cells triggered with bone marrow-derived dendritic cells cultured in the presence of retinoic acid.
Chau J; Moza D; Hossain N; Lee JK; Bienenstock J; Karimi K
Eur J Pharmacol; 2013 Sep; 715(1-3):321-7. PubMed ID: 23701916
[TBL] [Abstract][Full Text] [Related]
17. A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice.
Sun X; Somada S; Shibata K; Muta H; Yamada H; Yoshihara H; Honda K; Nakamura K; Takayanagi R; Tani K; Podack ER; Yoshikai Y
Gastroenterology; 2008 Feb; 134(2):447-58. PubMed ID: 18242212
[TBL] [Abstract][Full Text] [Related]
18. Expression of CD30 ligand and CD30 receptor in normal thyroid and benign and malignant thyroid nodules.
Trovato M; Villari D; Ruggeri RM; Quattrocchi E; Fragetta F; Simone A; Scarfi R; Magro G; Batolo D; Trimarchi F; Benvenga S
Thyroid; 2001 Jul; 11(7):621-8. PubMed ID: 11484890
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the CD30L binding domain on the human CD30 molecule using anti-CD30 antibodies.
Franke AC; Jung D; Ellis TM
Hybridoma; 2000 Feb; 19(1):43-8. PubMed ID: 10768840
[TBL] [Abstract][Full Text] [Related]
20. Study of gene expression of CD30 variant (CD30v) and CD30 ligand (CD30L) in acute leukemia.
Essa EA; El Halim SM; Abo-Elenin A; El Bendary A; Abdou SH; Farag W
Egypt J Immunol; 2007; 14(1):11-20. PubMed ID: 18689277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
